Beacon Biosignals announced an extension of its Series B financing, bringing the total round size to $97 million and cumulative funding to more than $132 million. The latest capital infusion adds new investors JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next, building on the company’s previously disclosed $86 million Series B led by a syndicate of healthcare and technology investors.
The company is focused on transforming brain health through scalable, at-home EEG technology paired with advanced analytics. Its platform is designed to support diagnostics, clinical trials, and precision medicine by capturing and interpreting real-world neural data.
Beacon Biosignals combines FDA-cleared wearable EEG devices with artificial intelligence to generate objective measures of brain function. The company works across neurology, psychiatry, and sleep medicine, providing tools for clinicians and biopharma partners to accelerate research and guide treatment development.
The new funding will be used to further scale Beacon’s platform, expand its analytics capabilities, and deepen its role in enabling data-driven approaches to brain health and therapeutic development.
KEY QUOTES:
“This milestone reflects strong momentum behind our vision to make brain health measurable, scalable, and actionable. We’re grateful for the support of our new and existing investors as we build the future of brain health.”
Jacob Donoghue, CEO of Beacon Biosignals
“Beacon is uniquely positioned to unlock the potential of brain data at scale. Their combination of clinical-grade EEG and advanced analytics is enabling a new era of discovery and precision in neuroscience. As novel therapeutics like psychedelics reshape the treatment landscape for psychiatric disease, platforms like Beacon’s will be critical for objectively measuring brain-based outcomes and accelerating development.”
Daniel Goldberg, Managing Director at Palo Santo VC
